FIGURE 1.

Representative technique for intraovarian insertion of platelet‐rich plasma (PRP) or enriched plasma cytokines. Sample from peripheral venipuncture (a) is processed to separate and activate fresh autologous platelets (b), which may be further incubated to yield enriched platelet factors (EPF) as a cell‐free condensate (b′). Relevant mediators in either PLT releasate preparation include platelet factor 4 (PF4) involved in PLT aggregation; interleukin‐1β (IL‐1β) a central inflammatory signal directing cell proliferation, differentiation, and apoptosis; and interleukin‐8 (IL‐8), which coordinates angiogenesis. Under direct ultrasound guidance, either activated PRP or EPF is injected into ovarian tissue via 19G single‐lumen in vitro fertilization needle. Periodic assessment of serum anti‐Mullerian hormone provides documentation of ovarian reserve response after treatment, including return of menses and follicular development